This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abiomed (ABMD) Beats on Q2 Earnings, Lowers FY22 Guidance
by Zacks Equity Research
Abiomed's (ABMD) strength in Impella product revenues drives its Q2 top line.
Earnings Estimates Rising for Abbott (ABT): Will It Gain?
by Zacks Equity Research
Abbott (ABT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Thermo Fisher (TMO) Beats on Q3 Earnings, Raises 2021 View
by Zacks Equity Research
Thermo Fisher (TMO) delivers a strong quarterly performance, leveraging on a significant rebound in its base business.
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
by Zacks Equity Research
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Masimo's (MASI) Q3 Earnings Surpass Estimates, '21 View Up
by Zacks Equity Research
Masimo's (MASI) robust product shipments, along with strong sensor sales, drive its Q3 sales.
Ecolab (ECL) Q3 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across the majority of its segments drives its Q3 sales despite pandemic-led business challenges.
Has Abbott Laboratories (ABT) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (ABT) Outperforming Other Medical Stocks This Year?
Abbott's (ABT) Organic Sales Grow Amid Spike in COVID Cases
by Zacks Equity Research
Within Nutrition, the robust year-over-year performance of Abbott's (ABT) U.S. pediatric and international adult nutrition arms drives the company in the third quarter.
Stock Market News for Oct 21, 2021
by Zacks Equity Research
The Dow and the S&P 500 ended near an all-time high on Wednesday, lifted by the Federal Reserve's latest Beige Book report that points to a modest growth pace of the US economy, and upbeat third-quarter earnings report.
Pre-Markets Opens Flat
by Zacks Equity Research
Pre-Markets Opens Flat
Markets Flat as Q3 Earnings Continue: VZ, ABT, TSLA & More
by Mark Vickery
Markets are flat in this morning's pre-market Hump Day, following a nice string of daily outperformance across indexes.
Abbott's (ABT) Q3 Earnings Beat Estimates, 2021 Guidance Up
by Zacks Equity Research
Abbott's (ABT) COVID-19 testing-related sales in Q3 increase on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Abbott (ABT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 52.17% and 15.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
5 Must-See Earnings Charts This Week
by Tracey Ryniec
What's going on in the economy? These five companies will give us some clues this week.
Abbott's (ABT) Nutrition Arm in Focus on Real Madrid Alliance
by Zacks Equity Research
According to Abbott (ABT), the partnership is set to support education, sports and social welfare activities of at-risk children in 80 countries.
Optimism Reenters The Market But Will It Last As Earnings Season Picks Up?
by Daniel Laboe
All the major averages have officially broken above their 50-day moving averages, a pivotal "risk-on" technical signal as we enter the heart of Q3 earnings season
Why Earnings Season Could Be Great for Abbott (ABT)
by Zacks Equity Research
Abbott (ABT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
PerkinElmer (PKI) Receives EUA from FDA for Latest Assay
by Zacks Equity Research
PerkinElmer's (PKI) latest test receives EUA from the FDA, thereby enabling qualified laboratories to detect and differentiate SARS-CoV-2, influenza A, influenza B and RSV.
This 1 Medical Stock Could Beat Earnings: Why It Should Be on Your Radar
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $117.57, marking a +0.49% move from the previous day.
BD's (BDX) Rotarex Atherectomy System Gets FDA 510 (k) Clearance
by Zacks Equity Research
BD's (BDX) Rotarex Atherectomy System receives expanded 510 (k) clearance from the FDA that can help in the treatment of in-stent restenosis in the United States.
The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Abbott Laboratories, UnitedHealth, Quest, and West Pharmaceutical
Analysts Estimate Abbott (ABT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PerkinElmer's (PKI) Arm Gets FDA EUA Nod for Latest Assay
by Zacks Equity Research
PerkinElmer's (PKI) unit receives FDA's EUA nod for its Anti-SARS-CoV-2 S1 Curve ELISA (IgG) that could aid in future understanding and provide insights on immune responses to SARS-CoV-2.
Growing COVID-19 Testing Demand to Boost Abbott's (ABT) Q3 Earnings
by Zacks Equity Research
Through July to September, Abbott's (ABT) Diagnostic business is likely to have benefited from the significant surge in the new COVID-19 case counts.